Nicola Goudie

Featured in:

Articles

Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transpla

Jun 27, 2024 | bmjopenrespres.bmj.com | Andrew Fisher |Michael White |Nicola Goudie |Anneka Kershaw

lung transplantationhealth economistChronic lung allograft dysfunction (CLAD) is the main contributor to the limited average life expectancy seen after lung transplantation. At present there are no proven treatments for reversing or reliably halting the damage to the transplanted lungs caused by CLAD.
Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transpla

Jun 27, 2024 | bmjopenrespres.bmj.com | Andrew Fisher |Michael White |Nicola Goudie |Anneka Kershaw

lung transplantationhealth economistChronic lung allograft dysfunction (CLAD) is the main contributor to the limited average life expectancy seen after lung transplantation. At present there are no proven treatments for reversing or reliably halting the damage to the transplanted lungs caused by CLAD.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.